001     292488
005     20250127163445.0
024 7 _ |a 10.1093/neuonc/noae176
|2 doi
024 7 _ |a pmid:39215664
|2 pmid
024 7 _ |a 1522-8517
|2 ISSN
024 7 _ |a 1523-5866
|2 ISSN
024 7 _ |a altmetric:168926182
|2 altmetric
037 _ _ |a DKFZ-2024-01735
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Hoa Ho, Kim
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Activation of Wnt/β-catenin signaling is critical for the tumorigenesis of choroid plexus.
260 _ _ |a Oxford
|c 2025
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1737971006_25370
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:A320#LA:A320# / DKFZ/ZMBH Alliance / 2025 Jan 12;27(1):106-122
520 _ _ |a Choroid plexus (ChP) is the secretory epithelial structure located in brain ventricles. Choroid plexus tumors (CPTs) are rare neoplasms predominantly occurring in young patients with intensified malignancy in children. CPT treatment is hindered by insufficient knowledge of the tumor pathology and limited availability of valid models.Genomic and transcriptomic data from CPT patients were analyzed to identify the putative pathological pathway. Cellular and molecular techniques were employed to validate bioinformatic results in CPT patient samples. Pharmacologic inhibition of Wnt/β-catenin signaling was assessed in CPT cells. Cell-based assays of ChP cell lines were performed following CRISPR-Cas9-derived knockout and over-expression of Wnt/β-catenin pathway genes. 3D CPT model was generated through CRISPR-Cas9-derived knockout of APC.We discovered that Wnt/β-catenin signaling is activated in human CPTs, likely as a consequence of large-scale chromosomal instability events of the CPT genomes. We demonstrated that CPT-derived cells depend on autocrine Wnt/β-catenin signaling for survival. Constitutive Wnt/β-catenin pathway activation, either through knock-out of the negative regulator APC or overexpression of the ligand WNT3A, induced tumorigenic properties in ChP 2D in vitro models. Increased activation of Wnt/β-catenin pathway in ChP organoids, through treatment with a potent GSK3β inhibitor, reduced the differentiation of mature ChP epithelia cells. Remarkably, the depletion of APC was sufficient to induce the oncogenic transformation of ChP organoids.Our research identifies Wnt/β-catenin signaling as a critical driver of CPT tumorigenesis and provides the first 3D in vitro model for future pathological and therapeutic studies of CPT.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a APC
|2 Other
650 _ 7 |a Brain tumor
|2 Other
650 _ 7 |a Wnt signaling
|2 Other
650 _ 7 |a choroid plexus organoid
|2 Other
650 _ 7 |a rare childhood cancer
|2 Other
700 1 _ |a Trapp, Marleen
|0 P:(DE-He78)7febcb2f4385ed4b379f34d11954e8e7
|b 1
|u dkfz
700 1 _ |a Guida, Catello
|0 P:(DE-He78)38a36539566d2f585597c49d5ee70c64
|b 2
|u dkfz
700 1 _ |a Ivanova, Ekaterina
|0 P:(DE-He78)64b69fa0317d5a02bd67528ceef097c2
|b 3
700 1 _ |a De Jaime-Soguero, Anchel
|b 4
700 1 _ |a Jabali, Ammar
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Thomas, Christian
|b 6
700 1 _ |a Salasova, Alena
|b 7
700 1 _ |a Bernatík, Ondřej
|b 8
700 1 _ |a Salio, Chiara
|b 9
700 1 _ |a Horschitz, Sandra
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Hasselblatt, Martin
|b 11
700 1 _ |a Sassoe-Pognetto, Marco
|b 12
700 1 _ |a Čajánek, Lukáš
|b 13
700 1 _ |a Ishikawa, Hiroshi
|b 14
700 1 _ |a Schroten, Horst
|b 15
700 1 _ |a Schwerk, Christian
|b 16
700 1 _ |a Acebrón, Sergio P
|b 17
700 1 _ |a Angel, Peter
|0 P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9
|b 18
|u dkfz
700 1 _ |a Koch, Philipp
|0 P:(DE-He78)7622d683a69f6d26d04f928d1b15d64b
|b 19
700 1 _ |a Patrizi, Annarita
|0 P:(DE-He78)7de884e25564c58f26d5c8dbed578256
|b 20
|e Last author
|u dkfz
773 _ _ |a 10.1093/neuonc/noae176
|g p. noae176
|0 PERI:(DE-600)2094060-9
|n 1
|p 106-122
|t Neuro-Oncology
|v 27
|y 2025
|x 1522-8517
909 C O |o oai:inrepo02.dkfz.de:292488
|p VDB
|p OpenAPC
|p openCost
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)7febcb2f4385ed4b379f34d11954e8e7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)38a36539566d2f585597c49d5ee70c64
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)64b69fa0317d5a02bd67528ceef097c2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)7622d683a69f6d26d04f928d1b15d64b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)7de884e25564c58f26d5c8dbed578256
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2024
915 p c |a APC keys set
|0 PC:(DE-HGF)0000
|2 APC
915 p c |a Local Funding
|0 PC:(DE-HGF)0001
|2 APC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-24
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURO-ONCOLOGY : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-24
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b NEURO-ONCOLOGY : 2022
|d 2023-10-24
920 2 _ |0 I:(DE-He78)A320-20160331
|k A320
|l A320 NWG Neuronal signaling and morphogenesis
|x 0
920 1 _ |0 I:(DE-He78)A320-20160331
|k A320
|l A320 NWG Neuronal signaling and morphogenesis
|x 0
920 1 _ |0 I:(DE-He78)A340-20160331
|k A340
|l A340 NWG Engeneering von Zellidentitäten und Krankheitsmodellen
|x 1
920 1 _ |0 I:(DE-He78)A100-20160331
|k A100
|l A100 Signaltransduktion/ Wachstumskontrolle
|x 2
920 0 _ |0 I:(DE-He78)A320-20160331
|k A320
|l A320 NWG Neuronal signaling and morphogenesis
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A320-20160331
980 _ _ |a I:(DE-He78)A340-20160331
980 _ _ |a I:(DE-He78)A100-20160331
980 _ _ |a APC
980 _ _ |a UNRESTRICTED
980 1 _ |a APC


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21